These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16533763)

  • 1. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
    Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
    Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
    Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
    Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y
    Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features.
    Guan M; Xu C; Zhang F; Ye C
    Int J Cancer; 2009 Jan; 124(1):88-94. PubMed ID: 18821581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of EphA5 by promoter methylation in human prostate cancer.
    Li S; Zhu Y; Ma C; Qiu Z; Zhang X; Kang Z; Wu Z; Wang H; Xu X; Zhang H; Ren G; Tang J; Li X; Guan M
    BMC Cancer; 2015 Jan; 15():18. PubMed ID: 25609195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
    Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
    Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
    Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
    Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGFBP7 promoter methylation and gene expression analysis in prostate cancer.
    Sullivan L; Murphy TM; Barrett C; Loftus B; Thornhill J; Lawler M; Hollywood D; Lynch T; Perry AS
    J Urol; 2012 Oct; 188(4):1354-60. PubMed ID: 22906661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma.
    Feng X; Ren C; Zhou W; Liu W; Zeng L; Li G; Wang L; Li M; Zhu B; Yao K; Jiang X
    Mol Carcinog; 2014 Nov; 53(11):858-70. PubMed ID: 23908159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter methylation of the DLC‑1 gene and its inhibitory effect on human colon cancer.
    Dai Z; Jin Y
    Oncol Rep; 2013 Sep; 30(3):1511-7. PubMed ID: 23783552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
    Kumar SR; Bryan JN; Esebua M; Amos-Landgraf J; May TJ
    BMC Cancer; 2017 Feb; 17(1):158. PubMed ID: 28235398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
    Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
    Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
    Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
    Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer.
    Yamada Y; Watanabe M; Yamanaka M; Hirokawa Y; Suzuki H; Takagi A; Matsuzaki T; Sugimura Y; Yatani R; Shiraishi T
    Cancer Sci; 2003 Jun; 94(6):536-9. PubMed ID: 12824880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
    Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
    Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
    Henrique R; Oliveira AI; Costa VL; Baptista T; Martins AT; Morais A; Oliveira J; Jerónimo C
    BMC Genomics; 2013 Dec; 14():898. PubMed ID: 24344919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.
    Zhang L; Zhang Q; Li L; Wang Z; Ying J; Fan Y; He Q; Lv T; Han W; Li J; Yang Y; Xu B; Wang L; Liu Q; Sun Y; Guo Y; Tao Q; Jin J
    J Mol Med (Berl); 2015 Jun; 93(6):691-701. PubMed ID: 25648635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
    Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
    Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
    Mitsui Y; Shiina H; Hiraki M; Arichi N; Hiraoka T; Sumura M; Honda S; Yasumoto H; Igawa M
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):487-96. PubMed ID: 22246902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.